دورية أكاديمية
أعرض في EDS

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.

التفاصيل البيبلوغرافية
العنوان: Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.
المؤلفون: Ivanova M; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Porta FM; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.; School of Pathology, University of Milan, 20122 Milan, Italy., Giugliano F; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Frascarelli C; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Sajjadi E; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Venetis K; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Cursano G; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Mazzarol G; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Guerini-Rocco E; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Criscitiello C; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Fusco N; Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
المصدر: Genes [Genes (Basel)] 2023 May 26; Vol. 14 (6). Date of Electronic Publication: 2023 May 26.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مواضيع طبية MeSH: Breast Neoplasms*/genetics , Breast Neoplasms*/therapy , Breast Neoplasms*/metabolism , Brain Neoplasms*/genetics , Brain Neoplasms*/therapy, Female ; Humans ; Prospective Studies ; Prognosis ; Breast/pathology
مستخلص: Breast cancer is the most frequently diagnosed malignancy worldwide and the leading cause of cancer-related death among women. Brain metastases are a primary contributor to mortality, as they often go undetected until late stages due to their dormant nature. Moreover, the clinical management of brain metastases is complicated by the relevant issue of blood-brain barrier penetration. The molecular pathways involved in the formation, progression, and colonization of primary breast tumors and subsequent brain metastases are diverse, posing significant hurdles due to the heterogeneous nature of breast cancer subtypes. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. In this review, we aim to highlight the biological mechanisms of breast cancer brain metastases by evaluating multi-step genetic pathways and to discuss currently available and emerging treatment strategies to propose a prospective overview of the management of this complex disease.
References: Cancers (Basel). 2021 Sep 29;13(19):. (PMID: 34638378)
Am Soc Clin Oncol Educ Book. 2017;37:45-56. (PMID: 28561683)
J Neurooncol. 2023 Mar;162(1):45-57. (PMID: 36884200)
Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411)
Lancet. 2017 Dec 17;388(10063):2997-3005. (PMID: 27908454)
J Clin Oncol. 2022 Feb 10;40(5):492-516. (PMID: 34932393)
Eur J Cancer. 2022 Aug;171:25-42. (PMID: 35696887)
Nat Rev Dis Primers. 2019 Jan 17;5(1):5. (PMID: 30655533)
Semin Cancer Biol. 2004 Jun;14(3):149-54. (PMID: 15246049)
Front Mol Biosci. 2022 Aug 26;9:894247. (PMID: 36090031)
Neurobiol Dis. 2010 Jan;37(1):13-25. (PMID: 19664713)
J Oncol Pharm Pract. 2022 Jul;28(5):1152-1156. (PMID: 35450470)
Nat Cancer. 2021 May;2(5):498-502. (PMID: 35122016)
Int J Mol Sci. 2020 Feb 21;21(4):. (PMID: 32098071)
Science. 2017 Mar 17;355(6330):1152-1158. (PMID: 28302823)
Nat Rev Clin Oncol. 2020 May;17(5):279-299. (PMID: 32080373)
Nat Rev Clin Oncol. 2022 Dec;19(12):763-774. (PMID: 36253451)
Nature. 2015 Nov 5;527(7576):100-104. (PMID: 26479035)
Cells. 2022 Nov 09;11(22):. (PMID: 36428975)
Cancer Cell. 2011 Apr 12;19(4):498-511. (PMID: 21481791)
Eur J Cancer Prev. 2022 Sep 1;31(5):459-466. (PMID: 35088973)
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13247-52. (PMID: 21788516)
Front Immunol. 2015 Aug 21;6:418. (PMID: 26347741)
Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935)
Cancer Res. 2019 Aug 15;79(16):4173-4183. (PMID: 31239270)
Cancers (Basel). 2022 Feb 28;14(5):. (PMID: 35267561)
Ann Biomed Eng. 2011 Aug;39(8):2223-2241. (PMID: 21556948)
Int J Mol Sci. 2019 Jan 25;20(3):. (PMID: 30691046)
EMBO J. 1996 May 15;15(10):2452-67. (PMID: 8665853)
Genes (Basel). 2020 Jun 28;11(7):. (PMID: 32605290)
Lancet Oncol. 2020 Apr;21(4):519-530. (PMID: 32171426)
Ther Adv Med Oncol. 2020 Jun 30;12:1758835920936151. (PMID: 32655700)
Cells. 2021 Jun 02;10(6):. (PMID: 34199522)
Cancer Res. 2000 May 1;60(9):2504-11. (PMID: 10811132)
Cancers (Basel). 2023 Mar 13;15(6):. (PMID: 36980630)
Neuro Oncol. 2021 Jun 1;23(6):894-904. (PMID: 33367836)
Cancer Res. 2008 Jul 15;68(14):5878-87. (PMID: 18632642)
Adv Funct Mater. 2020 Apr 3;30(14):. (PMID: 32440263)
NPJ Breast Cancer. 2022 Apr 7;8(1):46. (PMID: 35393462)
Front Oncol. 2017 Dec 11;7:298. (PMID: 29312881)
Expert Opin Investig Drugs. 2022 Jun;31(6):593-605. (PMID: 35311430)
Cancer Manag Res. 2023 Mar 23;15:311-317. (PMID: 36994110)
Anticancer Agents Med Chem. 2022;22(4):787-800. (PMID: 34229592)
Lancet Oncol. 2020 Mar;21(3):345-357. (PMID: 32035020)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
N Engl J Med. 2022 Jul 21;387(3):217-226. (PMID: 35857659)
Breast Cancer (Dove Med Press). 2022 Jan 10;14:1-13. (PMID: 35046721)
Cancer Manag Res. 2020 Jan 30;12:675-686. (PMID: 32099464)
BMC Cancer. 2018 Dec 7;18(1):1225. (PMID: 30526520)
Ann Oncol. 2020 Oct;31(10):1350-1358. (PMID: 32634611)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33239417)
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2900-9. (PMID: 25991856)
J Biol Chem. 1999 Oct 22;274(43):30557-62. (PMID: 10521438)
Clin Breast Cancer. 2020 Feb;20(1):e54-e64. (PMID: 31447286)
Breast Cancer Res. 2011;13(6):R125. (PMID: 22132754)
Acta Pharm Sin B. 2023 Jan;13(1):359-371. (PMID: 36815053)
Annu Rev Pathol. 2022 Jan 24;17:181-204. (PMID: 35073169)
Breast Cancer Res. 2016 Apr 27;18(1):43. (PMID: 27117582)
J Biol Chem. 2007 Nov 9;282(45):32689-98. (PMID: 17823122)
Ann Oncol. 2019 Mar 1;30(3):397-404. (PMID: 30475950)
Cell Rep. 2020 Jan 21;30(3):755-770.e6. (PMID: 31968251)
Front Oncol. 2020 Apr 02;10:422. (PMID: 32300557)
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. (PMID: 32468955)
BMC Cancer. 2021 Oct 28;21(1):1152. (PMID: 34706703)
ESMO Open. 2022 Oct;7(5):100561. (PMID: 36084395)
Front Oncol. 2023 Feb 20;13:1139372. (PMID: 36890829)
Neuro Oncol. 2020 Nov 26;22(11):1625-1636. (PMID: 32386414)
J Biol Chem. 2015 Apr 10;290(15):9842-54. (PMID: 25691572)
Nat Med. 2022 Sep;28(9):1840-1847. (PMID: 35941372)
Lancet Oncol. 2013 May;14(6):461-71. (PMID: 23602601)
Sci Rep. 2023 Feb 22;13(1):3108. (PMID: 36813833)
Br J Cancer. 2021 Oct;125(8):1056-1067. (PMID: 34226684)
Lancet. 2021 May 8;397(10286):1750-1769. (PMID: 33812473)
J Oncol Pract. 2018 Jul;14(7):437-441. (PMID: 29920138)
Front Biosci (Elite Ed). 2016 Jan 01;8(2):245-63. (PMID: 26709660)
Lancet Oncol. 2017 Jun;18(6):743-754. (PMID: 28526538)
Eur J Cancer Prev. 2023 Jul 1;32(4):364-369. (PMID: 37038998)
Ann Oncol. 2020 Nov;31(11):1526-1535. (PMID: 32828825)
Oncogene. 2016 Dec 1;35(48):6246-6261. (PMID: 27157615)
Breast. 2015 Aug;24(4):426-33. (PMID: 25881974)
Lancet Oncol. 2022 Jul;23(7):851-864. (PMID: 35671774)
Clin Transl Oncol. 2023 May;25(5):1218-1241. (PMID: 36897508)
Int J Cancer. 2023 Aug 15;153(4):803-814. (PMID: 36971103)
Ann Oncol. 2014 Jun;25(6):1116-21. (PMID: 24685829)
Oncologist. 2020 Nov;25(11):943-953. (PMID: 32869930)
J Appl Physiol (1985). 2013 Jan 1;114(1):19-27. (PMID: 23123353)
Neuro Oncol. 2023 Jan 5;25(1):157-166. (PMID: 35639825)
Cancers (Basel). 2022 Nov 30;14(23):. (PMID: 36497418)
Crit Rev Oncol Hematol. 2022 Apr;172:103643. (PMID: 35217131)
Neuro Oncol. 2022 Dec 1;24(12):2146-2158. (PMID: 35609559)
Glia. 2018 Nov;66(11):2438-2455. (PMID: 30357946)
Front Oncol. 2021 Mar 25;11:644737. (PMID: 33842357)
Int J Mol Sci. 2020 Sep 03;21(17):. (PMID: 32899139)
J Neurosci. 2003 May 15;23(10):4034-43. (PMID: 12764090)
Cells. 2019 Sep 20;8(10):. (PMID: 31547193)
Front Oncol. 2023 Feb 20;13:1003565. (PMID: 36890831)
Cancers (Basel). 2021 Aug 05;13(16):. (PMID: 34439105)
Gulf J Oncolog. 2021 Jan;1(35):36-41. (PMID: 33716211)
BMC Cancer. 2019 Nov 12;19(1):1091. (PMID: 31718602)
Cancer Metastasis Rev. 2020 Sep;39(3):711-720. (PMID: 32399646)
Front Oncol. 2023 Jan 25;13:978985. (PMID: 36761968)
Nature. 2009 Jun 18;459(7249):1005-9. (PMID: 19421193)
Nature. 2016 Apr 14;532(7598):195-200. (PMID: 27027288)
BMC Cancer. 2018 Sep 29;18(1):935. (PMID: 30268112)
Sci Transl Med. 2017 May 24;9(391):. (PMID: 28539475)
Int J Mol Med. 2017 Sep;40(3):755-761. (PMID: 28713912)
J Exp Med. 2003 Jun 2;197(11):1467-76. (PMID: 12782713)
Ann Oncol. 2021 Aug;32(8):994-1004. (PMID: 34219000)
ESMO Open. 2022 Dec;7(6):100636. (PMID: 36423363)
Cell Rep. 2017 May 9;19(6):1189-1201. (PMID: 28494868)
Clin Transl Oncol. 2014 May;16(5):436-46. (PMID: 24277572)
Front Mol Biosci. 2022 Mar 15;9:834651. (PMID: 35372498)
Nat Rev Cancer. 2002 Aug;2(8):563-72. (PMID: 12154349)
N Engl J Med. 2020 Feb 13;382(7):597-609. (PMID: 31825569)
Cancer Discov. 2011 Nov;1(6):481-6. (PMID: 22348200)
Ecancermedicalscience. 2020 Dec 03;14:1150. (PMID: 33574895)
J Clin Oncol. 2022 Oct 1;40(28):3246-3256. (PMID: 35584336)
Histopathology. 2017 May;70(6):906-917. (PMID: 28072477)
JCO Precis Oncol. 2020 May 27;4:. (PMID: 32923889)
J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32859740)
J Med Genet. 2018 Jul;55(7):431-441. (PMID: 29929997)
Breast. 2023 Jun;69:312-322. (PMID: 36996620)
Gland Surg. 2020 Oct;9(5):1328-1337. (PMID: 33224807)
Cancers (Basel). 2020 Jun 17;12(6):. (PMID: 32560361)
Nat Med. 2018 Jul;24(7):1024-1035. (PMID: 29892069)
Lancet Oncol. 2016 Jul;17(7):976-983. (PMID: 27267608)
Oncology. 2023;101(4):262-269. (PMID: 36809751)
Cell. 2014 Feb 27;156(5):1002-16. (PMID: 24581498)
Neurooncol Adv. 2022 Sep 30;4(1):vdac154. (PMID: 36299795)
J Chin Med Assoc. 2023 Feb 1;86(2):207-219. (PMID: 36652567)
Am J Pathol. 2013 Jul;183(1):83-95. (PMID: 23665199)
Cells. 2023 Mar 08;12(6):. (PMID: 36980181)
Front Oncol. 2022 Jun 27;12:905065. (PMID: 35832552)
Oncologist. 2021 Oct;26(10):835-844. (PMID: 34105210)
Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. (PMID: 35240902)
Br J Pharmacol. 2023 Feb 12;:. (PMID: 36775813)
N Engl J Med. 2018 Aug 23;379(8):753-763. (PMID: 30110579)
Oncogene. 2016 Jun 2;35(22):2881-92. (PMID: 26411365)
فهرسة مساهمة: Keywords: biomarkers; brain metastasis; breast cancer; metastatic breast cancer; molecular profiling
تواريخ الأحداث: Date Created: 20230628 Date Completed: 20230629 Latest Revision: 20230701
رمز التحديث: 20230701
مُعرف محوري في PubMed: PMC10298724
DOI: 10.3390/genes14061160
PMID: 37372340
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4425
DOI:10.3390/genes14061160